All journal articles

Compound research

Tissue signalling peptides: what the research actually shows

What tissue-signalling research measures, why the term healing peptides outruns the evidence, and where BPC-157, TB-500, GHK-Cu and KPV research stops.

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

Tissue-signalling research studies how cells respond to chemical messages: whether cultured cells migrate across a gap, whether new blood vessels form in a model system, and what changes in a standardised animal wound model. The peptides most often searched for as “healing peptides”, among them BPC-157, TB-500, thymosin beta-4, GHK-Cu and KPV, appear in that literature almost entirely in cell culture and animal experiments. None of them is a licensed medicine in the United Kingdom. A measured change in a dish or in a rodent is a finding about that model, not a clinical result in people, and this article is about where that boundary sits.

What does tissue-signalling research actually measure?

Three experimental designs account for most of the published work on these compounds. Each measures something narrow and well defined.

Design What is measured What it does not measure
Cell migration (scratch) assay Movement of cultured cells into a scratch made in a monolayer, from images taken over hours Anything about an intact organism: no circulation, no immune response, no mechanical loading
Angiogenesis assay One step of vessel formation, such as endothelial tube formation in vitro or vessel growth in a membrane or animal model Whether a change in vessels alters any outcome that matters to a patient
Animal wound model A standardised lesion in a rodent, with endpoints such as area over time, histology or tissue composition Human endpoints such as pain, function or return to activity, which these designs do not record

The people who develop these assays are explicit about the limits. The 2007 Nature Protocols description of the in vitro scratch assay presents it as a convenient and inexpensive way to measure cell migration that mimics, to some degree, migration during wound closure in vivo, which is a statement about resemblance rather than equivalence. The 2018 consensus guidelines on angiogenesis assays in Angiogenesis make the point more bluntly: using a bioassay that studies part of a process inherently implies accepting specific limitations, and cellular in vitro systems represent only a surrogate of in vivo conditions. Both are legitimate tools for mechanistic questions. The error is treating an endpoint from one of them as a clinical endpoint.

“Healing peptides”: why the phrase outruns the evidence

“Healing peptides” is a consumer search phrase, not a scientific category. No regulator, pharmacopoeia or research field defines a class of peptides by that name, and the compounds grouped under it have different structures, different proposed mechanisms and very different amounts of evidence behind them.

The phrase also carries a regulatory problem. Under the Human Medicines Regulations 2012, a product presented as treating or preventing disease, or as restoring, correcting or modifying physiological functions in people, is a medicine. In April 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) said that if clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under those regulations. As reported by Aesthetics Journal, the agency identified claims that BPC-157 helps “tissue repair and recovery from injuries” as impermissible.

That is why this journal describes studies rather than outcomes: which compound was used, in which model, what was measured, and what the authors reported. It is also why a supplier cannot responsibly answer the question the search phrase implies.

Why a cell or animal finding is not a clinical result

Four gaps separate the two, and all four apply to the compounds below.

  • The system. A cell line in a dish lacks the circulation, immune response and mechanical environment of living tissue. A rodent is not a small human: skin structure, tendon loading and the time course of wound closure all differ.
  • The endpoint. Faster closure of a scratch in a monolayer and a clinically meaningful change in a person are different quantities, measured on different scales over different timeframes.
  • The exposure. In a dish, a known concentration is applied directly. In an organism, what reaches a tissue depends on stability, distribution and clearance, which are often unmeasured in these studies.
  • The design. Preclinical work rarely has the blinding, randomisation, comparator and sample size that would let an effect be estimated reliably in people.

The scale of that gap is documented. A 2025 systematic review in HSS Journal looking at BPC-157 in orthopaedic sports medicine identified 36 relevant studies: 35 were preclinical and one was a retrospective clinical study. The authors found no clinical safety data.

What the published research covers, compound by compound

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide whose sequence derives from a protein found in gastric juice. The research base is animal and cell work: a 2003 rat Achilles tendon study, a 2010 study of tendon outgrowth, cell survival and cell migration, and a 2017 study in the Journal of Molecular Medicine that used chick chorioallantoic membrane and endothelial tube-formation assays together with a rat hind-limb ischaemia model and reported increased vessel density and changes in VEGFR2 signalling in those systems. The 2025 systematic review above is the clearest statement of the limits: almost entirely preclinical, with no clinical safety data. Evidence level: in vitro and animal.

TB-500 and thymosin beta-4

These two names are routinely conflated, and the distinction is the most important thing on this page. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a trade name: doping-control analytical work describes it as a synthetic version of LKKTETQ, the seven-amino-acid segment at positions 17–23 of thymosin beta-4. A 1999 study that is frequently cited in this area used full-length thymosin beta-4 in cell-migration and rodent wound models, not the short fragment. Findings for a 43-residue protein do not transfer automatically to a seven-residue fragment, which is why the sequence on the batch report matters more than the product name. Our article on BPC-157 and TB-500 works through this in detail. Evidence level: in vitro and animal, with the molecule studied often differing from the molecule supplied.

GHK-Cu

GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine, first identified in human plasma. A 1993 rat wound-chamber study examined connective-tissue accumulation, and a 2018 review in the International Journal of Molecular Sciences by Pickart and Margolina collates the cell, animal and gene-expression work. A review summarises existing studies; it is not itself clinical evidence. See our GHK-Cu guide for the copper chemistry. Evidence level: in vitro, animal and review.

KPV

KPV is the tripeptide lysine-proline-valine, corresponding to the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). Two 2008 studies examined it in human intestinal cell lines and in mouse models of colitis and reported reduced inflammatory signalling, with one showing uptake through the PepT1 transporter. Evidence level: cell lines and mouse models.

These four are also sold together as a blend, which adds an attribution problem on top of the evidence problem: see what is KLOW peptide.

Thistle supplies BPC-157 — 10mg Research Peptide at £27.99 and TB-500 — 10mg Research Peptide at £34.99, each with a batch laboratory report.

Checking the material before the experiment

For this group of compounds, documentation does more work than usual, because the names are loose and the fragments are short.

  • Confirm the sequence, not just the mass. Short fragments and single-residue variants can be close in mass. For anything sold as TB-500, the stated sequence is the only way to know which molecule is in the vial.
  • Match the batch number on the vial label to the laboratory report, and check the report date and the method used.
  • Read a purity figure for what it is. A high-performance liquid chromatography (HPLC) area percentage describes a separation under one method. It is not a statement of identity, content or sterility.
  • Record what you actually used, including the counterion and the storage history, so that a negative finding can be interpreted later.
  • Match the molecule to the literature you are building on. If the cited study used full-length thymosin beta-4, a fragment is a different experiment, not a cheaper version of the same one.

Thistle shows a laboratory report for the current batch on each product page, and any batch can be checked through our batch report lookup. For how to read one of these documents, see how to read a peptide COA.

UK status and anti-doping status

None of these compounds holds a UK marketing authorisation as a medicine, and they are supplied as research materials for laboratory use. None is listed as a controlled drug in Schedule 2 to the Misuse of Drugs Act 1971. The MHRA position described above concerns how a product is presented: medicinal claims can bring a product within the Human Medicines Regulations 2012, whatever the seller calls it.

Sport has separate rules, and two of these compounds are named on the World Anti-Doping Agency’s 2026 Prohibited List. BPC-157 appears under S0, non-approved substances. Thymosin-β4 and its derivatives, with TB-500 given as the example, appear under S2.3, growth factors. Anyone subject to anti-doping rules should check the current list directly for any other compound, including GHK-Cu and KPV, rather than inferring a status from this page.

This section is general information, not legal advice.

Tissue signalling peptide FAQs

What are “healing peptides”?

It is a search phrase rather than a defined class. The compounds it is applied to have been studied mainly in cell culture and animal models, and that literature does not establish outcomes in people. None is a licensed medicine in the UK.

Is there human evidence for BPC-157 or TB-500?

Very little. The 2025 systematic review of BPC-157 in orthopaedic sports medicine found 35 preclinical studies, one retrospective clinical study and no clinical safety data. For TB-500, the widely cited work used full-length thymosin beta-4 rather than the fragment sold under that name.

Are these compounds safe to use, and what are the side effects?

There are no human safety or use data for these research materials as supplied. They are not for human use, and we give no advice on personal use, preparation or administration.

Is TB-500 the same thing as thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a trade name for a synthetic peptide based on a seven-amino-acid segment of it, at positions 17–23. Check the sequence on the batch report rather than relying on the name.

Are they banned in sport?

BPC-157 is listed on the 2026 World Anti-Doping Agency Prohibited List under S0, and thymosin-β4 and its derivatives, including TB-500, under S2.3.

Sources

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.

Educational information only. This journal does not recommend a substance for personal use or provide medical advice.